JP2017510595A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510595A5
JP2017510595A5 JP2016560952A JP2016560952A JP2017510595A5 JP 2017510595 A5 JP2017510595 A5 JP 2017510595A5 JP 2016560952 A JP2016560952 A JP 2016560952A JP 2016560952 A JP2016560952 A JP 2016560952A JP 2017510595 A5 JP2017510595 A5 JP 2017510595A5
Authority
JP
Japan
Prior art keywords
carboxamide
anilino
dihydropyrimido
indolizine
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510595A (ja
JP6518690B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/056839 external-priority patent/WO2015155042A1/en
Publication of JP2017510595A publication Critical patent/JP2017510595A/ja
Publication of JP2017510595A5 publication Critical patent/JP2017510595A5/ja
Application granted granted Critical
Publication of JP6518690B2 publication Critical patent/JP6518690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560952A 2014-04-07 2015-03-30 (5,6−ジヒドロ)ピリミド[4,5−e]インドリジン Active JP6518690B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734.8 2014-04-07
EP14163734 2014-04-07
EP15153207 2015-01-30
EP15153207.4 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (3)

Publication Number Publication Date
JP2017510595A JP2017510595A (ja) 2017-04-13
JP2017510595A5 true JP2017510595A5 (enExample) 2018-05-17
JP6518690B2 JP6518690B2 (ja) 2019-05-22

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560952A Active JP6518690B2 (ja) 2014-04-07 2015-03-30 (5,6−ジヒドロ)ピリミド[4,5−e]インドリジン

Country Status (16)

Country Link
US (3) US9856258B2 (enExample)
EP (1) EP3129374B1 (enExample)
JP (1) JP6518690B2 (enExample)
KR (1) KR102432420B1 (enExample)
CN (1) CN106132963B (enExample)
AU (1) AU2015243694B2 (enExample)
BR (1) BR112016022342B1 (enExample)
CA (1) CA2944610C (enExample)
DK (1) DK3129374T3 (enExample)
ES (1) ES2716165T3 (enExample)
HU (1) HUE043108T2 (enExample)
MX (1) MX368767B (enExample)
PL (1) PL3129374T3 (enExample)
PT (1) PT3129374T (enExample)
RU (1) RU2692479C2 (enExample)
WO (1) WO2015155042A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3129374T3 (en) * 2014-04-07 2019-04-08 Netherlands Translational Res Center B V (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
JP6912486B2 (ja) * 2016-02-19 2021-08-04 フェニックス モレキュラー デザインズ Rsk阻害剤として有用なカルボキサミド誘導体
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
WO2018172984A1 (en) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
KR20210126077A (ko) 2019-02-11 2021-10-19 피닉스 몰레큘라 디자인스 Rsk 억제제의 결정형
MX2024007450A (es) * 2021-12-15 2024-07-04 Sillajen Inc Combinaciones farmaceuticas para utilizarse en el tratamiento de enfermedades neoplasicas.
AU2022408915B2 (en) * 2021-12-15 2026-05-14 Sillajen, Inc. Methods of treating neoplastic diseases
KR20240096905A (ko) * 2021-12-15 2024-06-26 신라젠(주) 변형된 베타-사이클로덱스트린을 포함하는 약제학적 조성물
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337142B2 (en) * 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
EA010904B1 (ru) 2003-05-22 2008-12-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
US8207180B2 (en) 2006-11-28 2012-06-26 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
AU2009264431B2 (en) * 2008-06-26 2013-11-07 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
ES2660146T3 (es) 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
CN102470136B (zh) 2009-07-29 2013-12-25 内尔维阿诺医学科学有限公司 Plk 抑制剂的盐类
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
CA2821829A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
RU2591191C2 (ru) * 2011-01-26 2016-07-10 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы
EP3013823B1 (en) 2013-06-24 2017-11-01 Merck Patent GmbH Imidazole compounds as modulators of fshr and uses thereof
DK3129374T3 (en) * 2014-04-07 2019-04-08 Netherlands Translational Res Center B V (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER

Similar Documents

Publication Publication Date Title
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
CA2934137C (en) Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments
JP2015514808A5 (enExample)
EP3555074B1 (en) Aminopyrazoles as selective janus kinase inhibitors
JP2019505541A5 (enExample)
JP2005539012A5 (enExample)
JP2017502940A5 (enExample)
JP2021509113A (ja) キナーゼ阻害剤としての複素環式アミド
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
JP2010526129A5 (enExample)
EA024406B1 (ru) АМИНОСПИРТ-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ХИНАЗОЛИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
JP2017525668A5 (enExample)
JP2017519781A5 (enExample)
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
JP2015505301A5 (enExample)
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
CA3095233A1 (en) 4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders
MX2023002907A (es) Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300.
RU2007130153A (ru) Амидные производные
JP2017510595A (ja) (5,6−ジヒドロ)ピリミド[4,5−e]インドリジン
JP2019536764A5 (enExample)
JP2016525142A5 (enExample)
WO2019224774A1 (en) Heterocyclic amides as rip1 kinase inhibitors
MX2023014589A (es) Compuestos anticancer.